Internship
Analytical Data Science – CMC Intern
Confirmed live in the last 24 hours
Legend Biotech
1,001-5,000 employees
Develops and commercializes cell therapies
No salary listed
Somerset County, NJ, USA
This is a hybrid position, indicating a mix of remote and in-office work.
Upload your resume to see how it matches 10 keywords from the job description.
PDF, DOC, DOCX, up to 4 MB
- Second- or third-year Science or Engineering undergraduate student with skills in data modeling that enables efficient data exploration, data reporting and easier future maintainability
- Skills and experience and/or working knowledge of Power BI as an example, or other type of easy to maintain database and data modeling applications
- Excellent written and verbal communication skills
- Motivated, highly organized and multi-tasking skills
- Ability to work independently and as a team player
- Ability to learn and understand scientific data in CGT settings (Flow cytometry analysis of CGT product for example)
- Collecting and consolidating scientific data for analytical development (ELN, analytical instrument data storage source)
- Creating database to store the collected data according to defined specifications and attributes
- Apply statistical tool to facilitate the exploration of various figures to support data analysis and scientific interpretation
- Interact with AD scientist and leadership to understand the scope of the project and be able to provide the database and statistical tools within the targeted timeline
Legend Biotech develops and sells cell therapies aimed at treating serious diseases, particularly cancers like hematological malignancies and solid tumors. Their approach is technology agnostic, allowing them to explore various methods to find effective treatments. The company operates in the personalized medicine sector, focusing on discovering, developing, and bringing new therapies to market. They generate revenue through licensing and selling their therapies, including CAR-T therapies, which involve modifying a patient's own cells to combat cancer. Unlike many competitors, Legend Biotech emphasizes transparency with investors, regularly updating them on financial results and business developments. Their goal is to provide effective treatments for hard-to-treat diseases.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Franklin Township, New Jersey
Founded
2014
Simplify's Take
What believers are saying
- $150M investment in Belgium facility shows commitment to expanding production capabilities.
- Alan Bash's appointment strengthens leadership in CAR-T therapy market.
- New R&D facility in Philadelphia focuses on next-generation cell therapies.
What critics are saying
- Increased competition from Amgen's Imdelltra could impact market share.
- Collaboration with Multiply Labs may face challenges in scaling up production.
- Expansion of R&D facilities requires significant investment, potentially straining resources.
What makes Legend Biotech unique
- Legend Biotech focuses on novel cell therapies for oncology, including CAR-T and NK cells.
- The company is technology agnostic, exploring multiple platforms for effective treatments.
- Legend Biotech's business model includes discovery, development, and commercialization of therapies.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
Paid Sick Leave
Paid Holidays
Remote Work Options
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 0%J&J, Legend to invest $150M in Belgium cell therapy facility as new Carvykti rival looms.
Legend Biotech Corporation (LEGN) is developing a promising CAR-T cancer drug in partnership with Johnson & Johnson.
Legend Biotech Corporation on Tuesday said it appointed Alan Bash as president of its CAR-T product CARVYKTI®. In this newly created role, Bash will be responsible for managing the continued growth of CARVYKTI®, overseeing the Somerset-based firm’s commercial, technical operations, and quality functions of the franchise.“This expansion in our leadership structure is on the heels of CARVYKTI’s recent successes, including recent approvals from the U.S. Food and Drug Administration and European Commission for label expansion,” Ying Huang, chief executive officer of Legend Biotech said. “Legend Biotech welcomes Alan and is confident that his wealth of operational knowledge in oncology will help further strengthen the Company’s leadership role in the treatment of multiple myeloma.”Previously, Bash served as chief executive officer for two oncology-focused biotech companies, most recently at ZielBio, and before that, as president and CEO at Checkmate Pharmaceuticals. He also had a 23-year career with Bristol Myers Squibb, where he held various leadership positions across all major therapeutic areas—including oncology—driving the U.S. launch of Opdivo® and the expansion of additional cancer treatments such as Yervoy® and Erbitux ®.Bash contributed to several blockbuster products in collaboration with other companies, including Abilify® with Otsuka and Eliquis® with Pfizer.“As the fastest launched CAR-T product on the market, CARVYKTI has already produced impressive momentum,” Bash said
SOMERSET, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced the appointment of Alan Bash as the Company’s President of CARVYKTI®. In this newly created role, Mr. Bash will be responsible for managing the continued growth of CARVYKTI®, overseeing Legend Biotech’s commercial, technical operations, and quality functions of the franchise.“This expansion in our leadership structure is on the heels of CARVYKTI’s recent successes, including recent approvals from the U.S. Food and Drug Administration and European Commission for label expansion,” said Ying Huang, Ph.D., Chief Executive Officer of Legend Biotech. “Legend Biotech welcomes Alan and is confident that his wealth of operational knowledge in oncology will help further strengthen the Company’s leadership role in the treatment of multiple myeloma.”Mr
With a global workforce of 1,500 employees, including 350 in R&D, Legend is expanding its manufacturing capabilities with new facilities in New Jersey and beyond.